June 13, 2017
NEWS FROM THE NCI
Sharpless
Dr. Norman "Ned" Sharpless Selected as Director of NCI
Norman-Ned-Sharpless
Ned Sharpless
President Donald Trump announced his intention to appoint Norman "Ned" Sharpless, MD as Director of the National Cancer Institute (NCI). Dr. Sharpless is a physician and director of the Lineberger Comprehensive Cancer Center at University of North Carolina. 

Douglas Lowy, MD has served as NCI Acting Director since Harold Varmus, MD stepped down in spring of 2015. 

Related

MEMBER HIGHLIGHTS
BETRNet
Case Western Reserve University Receives $6 Million to Continue Research on Barrett's Esophagus
The National Cancer Institute recently awarded a $6 million grant to the Case Comprehensive Cancer Center and Case Western Reserve University School of Medicine to continue research on Barrett's Esophagus, a potentially fatal condition associated with long-term gastroesophageal reflux. Tissue lining the esophagus transforms into tissue similar to that found in the intestine, significantly increasing esophageal cancer risk.

The highly competitive five-year award provides resources to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma. As a competitive renewal, the award extends a 2011 grant that provided  $5.4 million to investigate genetic biomarkers related to the condition.

Funding supports the Barrett's Esophagus Translational Research Network (BETRNet) Research Center administered by Case Western Reserve University. The research will develop a new molecular marker based method for detection of Barrett's esophagus that was invented as Case Western Reserve University and University Hospitals Cleveland Medical Center. The new research will span six additional institutions including the Fred Hutchinson Cancer Research Center, Cleveland Clinic, Johns Hopkins University, Mayo Clinic, Washington University St. Louis, and University of North Carolina Chapel Hill. The network includes basic science and clinical researchers working to find new ways to identify, monitor, and improve outcomes for patients at risk of Barrett's Esophagus.

Chak, Amitabh
Amitabh Chak
"The team has been working together for several years," said  Amitabh Chak, MD, MS, contact Principal Investigator on the award and Director of Clinical Research in the Division of Gastroenterology and Liver Disease at UH Cleveland Medical Center. "This award affirms the exciting progress we have already made in detection, prediction, prevention, and treatment of Barrett's Esophagus and esophageal cancer." more>
MARK YOUR CALENDARS
annual-retreat
Case CCC Annual Scientific Retreat
Jul 20 | Tinkham Veale, CWRU campus
The Case Comprehensive Cancer Center Annual Scientific Retreat will be held July 20, 2017 at the Tinkham Veale University Center on CWRU campus. We will kick-off the retreat in the afternoon with a keynote presentation from Ramon Parsons, MD, PhD, Professor and Chairman, Oncological Sciences, Icahn School of Medicine at Mount Sinai, followed by a Director's Overview by Case CCC Director Stan Gerson, MD.

A cocktail reception with heavy hors d'oeuvres will follow the presentations, allowing you the chance to network with your colleagues.

We will once again have poster presentations by students, postdocs and fellows. Poster judging be conducted prior to the start of the program (2:30-4:30p), and the poster presentation session will run concurrently with the cocktail reception (6-8p). This is your chance to view the incredible research being conducted by the next generation of cancer researchers. Please encourage your trainees, fellows and students to submit an abstract.

Please plan to set aside the time to participate in this year's retreat. Register early, and we will see you there!
ASCO Review 2017: Highlights of the National Meeting
Jun 28, 2017 | InterContinental Hotel
ASCO Review 2017 The goal of this course is to provide practicing hematologists, medical oncologists, radiation oncologists, and oncology nurses with current data and information that was presented at the annual National ASCO Meeting. As a result of attending this conference, the participant should be able to:
  • Describe the current treatment options and updates in various cancer modalities,
  • Discuss the development and outcomes of clinical cancer research,
  • Assess the emerging role of novel therapeutics in oncology
CME credits will be offered. 
Call for Abstracts: Mesenchymal Stem Cell (MSC) Conference 
Aug 14-16 | Marriott Key Center, Downtown
The National Center for Regenerative Medicine (NCRM) invites you to submit an abstract for the upcoming 2017 MSC Conference

The following will be selected from submissions:  Short talks;  Lightning talks;  Young Investigator award;  Best Abstract award.

Abstract Categories:
  • MSC Sources for Derivation
  • Disease Models for Adult Stem Cell Therapy
  • Immunomodulation Using Adult Stem Cells
  • Gene Therapy on Adult Stem Cells 
  • Regenerative Medicine and Adult Stem Cells
  • Tissue Engineering
  • Cell Biology in the Clinical Setting
  • Clinical Trials (Academic & Corporate)
  • MSC Technologies

Rolling submission deadlineJul 21

International Cancer Education Conferenceicec
Sep 13-15 | Westin Cleveland Downtown
ICEC 2017 The International Cancer Education Conference is the only meeting in North America totally dedicated to cancer education - ranging from medical professionals to patients and community education.  Register to attend this meeting of national and international specialists in cancer education, survivorship and palliative care focused on advocacy, scientific investigation, program and curriculum development, skill training, and evaluation.  National leaders will be presenting special programs on grant writing (National Cancer Institute), cancer and the elderly (Cancer and Aging Research Group), surgical oncology (American College of Surgeons), plus dedicated mentoring opportunities will be available to present to content experts.

Graft versus Host Disease National Symposium
Oct 13 | Grand Event Center - Columbus
The GvHD National Conference focuses on cutting edge research and new treatments, consists of two tracks: one for physicians and other health care professionals, and one for BMT survivors, their families and their caregivers. The Meredith A. Cowden Foundation in collaboration with the Case CCC, UH Seidman Cancer Center, and Cleveland Clinic Taussig Cancer Institute, created the National GvHD Health Symposium in 2010 to raise awareness about Graft vs. Host Disease (GvHD), to promote research to further our understanding of its cause, and to review cutting edge approaches to prevention and treatment. Over 1,200 people have attended this event, which provides an opportunity for attendees to interact with some of the world's leading authorities on GvHD, a complication that affects over 60% of bone marrow transplant patients. This year we are excited to team up with the The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute as hosts of the 2017 symposium! CME credits will be offered. Register today
Cleveland Clinic's 2017 Medical Innovation Summit 
Oct 23-25 | Huntington Convention Center
Cleveland Clinic's Medical Innovation Summit  will bring together more than 2,250 of the brightest leaders from around the world to downtown Cleveland to discuss transformative technologies that will deliver on the powerful promise of genomics and precision medicine.

Now in its 15 th year, the annual Medical Innovation Summit is organized by  Cleveland Clinic Innovations, the development and commercialization arm of Cleveland Clinic, which has developed 77 spin-off companies since it was founded in 2000.

The  agenda includes thought-provoking panels, as well as lively 1-on-1 discussions with top healthcare, industry and biotech leaders. Topics include: next-generation genomic sequencing; the gene therapy and gene editing markets; artificial intelligence and decision support technologies; customized implants and robotics; the investors' perspective on precision medicine; and reimbursement strategies for genomic innovation.

The 2017 Medical Innovation Summit will be held at the Huntington Convention Center in downtown Cleveland.   Registration is now open .
CASE CCC IN THE NEWS
VIDEO: Financial toxicity, limited reimbursements remain unaddressed for patients with cancer
Helio/HemOnc Today - Jun 9, 2017
Financial toxicity associated with cancer diagnoses appeared to be a common theme at the ASCO Annual Meeting, according to Brian Bolwell, MDchairman of the Taussig Cancer Institute of Cleveland Clinic Foundation and Associate Director, Case Comprehensive Cancer Center. 
The Guardian - Jun 2, 2017
More children are surviving childhood cancer with fewer debilitating long-term side effects, a new study has found..."Perhaps no other area of oncology has seen such dramatic progress in treatment over the past decades as childhood cancer," said Timothy D Gilligan, a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center member, who was not involved in the study. 
Urology Times - Jun 5, 2017
Diagnostic magnetic resonance imaging (MRI) strategies for the diagnosis of prostate cancer should be considered prior to biopsy of suspicious lesions, according to the results of a study published online in  Radiology (2017 May 17:162181)..." We believe that the adoption of these strategies could be very beneficial to the patient and the health care system," Vikas Gulani, MD, PhD, of Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, told Urology Times on behalf of him and his partner Lee E. Ponsky, MD. "The patient benefits with fewer biopsy-related complications and more accurate diagnosis and triaging of disease. We hope this study will provide sufficient evidence that will allow MRI prior to biopsy to be incorporated into management algorithms."
FUNDING OPPORTUNITIES
Opportunities for Pilot Projects in Cancer Immunotherapy
DEADLINE: Jun 23, 2017
Through philanthropic funds made available to the Case CCC, applications for collaborative pilot projects are requested from investigators focused on the understanding of cancer immunology and the investigation of novel immunotherapy approaches. The main goal of this RFA is to stimulate novel research designed to take maximum advantage of new scientific discoveries and technologies and contribute to advances in cancer immunotherapy. To enhance the development of Immune Monitoring capacity within the Case CCC, proposals that emphasize the use of multi-parameter flow cytometry, multi-spectral immunohistochemistry, muti-omics and/or tissue repositories are particularly sought after.
Opportunities for Pilot Projects in GU Malignancies
DEADLINE: Jun 23, 2017
The Case CCC will provide seed money to foster collaborations and to promote and increase institution-wide capacity and competitiveness in the investigation of genitourinary malignancies. Based on the quality of the applications, up to 2 pilots of up to $75,000 will be awarded to investigators who intend to gather preliminary data to be used in seeking future extramural and nationally-competitive funding. Case CCC members with a faculty appointment at all levels are encouraged to apply (applicants must be eligible to apply as PIs of nationally competitive research grants - postdoctoral fellows, graduate students and research associates are not eligible to apply for these pilot funds). Proposals from both junior and senior investigators are encouraged. Demonstrated feasibility to develop into a externally funded research project within two years and a plan for competing for such funding is a required component of the pilot application. Projects submitted for review must be distinct from currently funded research and describe new projects that could not be achieved without the collaboration and pilot funds.
phase1Case CCC Funding for Pilot/Phase I Clinical Trials
Deadline: Rolling 
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.

The proposals are being accepted on a rolling basis subject to availability of funds.

Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office,  katarzyna.karelus@case.edu, 216.844.4176.
NIH BULLETIN- Notices and Funding Opportunities
rfas 
Call for Applications/Program Announcements


HIV/AIDS and the Tumor Niche (R01)(RFA-CA-17-030)
Deadline: August 7, 2017

Pediatric Early Phase Clinical Trials Network (UM1)(RFA-CA-17-027)
Deadline: Aug 16, 2017

PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])(PA-17-302)
Deadline: Sep 5, 2017; Jan 5, 2018; Apr 5, 2018

PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])(PA-17-303)
Deadline: Sep 5, 2017; Jan 5, 2018; Apr 5, 2018

Administrative Supplements for Research on Dietary Supplements (Admin Supp)(PA-17-307)
Deadline: Oct 15, 2017; Jan 15, 2018; Apr 15, 2018
EVENTSevents
Wed, Jun 14
Hem/Onc Division Research Conf
Stephanie Kim, MD
Fellow, Hem/Onc, CWRU/UH
"TGF-beta in Esophageal Adenocarcinoma"
and
Priyanka Bhateja, MD
Fellow, Div. of Hem/Onc, CWRU/UH
"Genomics in Non-small Cell Lung Cancer"
8a Lerner B-151

PRCHN Seminar
Don Hedeker, PhD, Professor, Biostatistics, University of Chicago
"Approaches to Multi-Level Modeling"
12p BioEnterprise Bldg
Thurs, Jun 15
Developmental Therapeutics Journal Club
9a R4-013
Fri, Jun 16
TCI Grand Rounds
Stephanie Terezakis, MD
Johns Hopkins
"Hodgkin's Lymphoma: Lessons Learned from Children"
8a R3/002-003

Pediatric Basic Science Research Seminar Series
Amir Avishai, PhD
Administrative Director, Swagelok Center for Surface Analysis of Materials, CWRU
and
Kevin Abbasi, PhD
Research Engineer, Swagelok Center for Surface Analysis of Materials, CWRU
"Structural & Compositional Analysis Solutions for Biology and Medical Research"
9a BRB 832
Mon, Jun 19
Genomic Medicine Institute 
Siddhesh Aras, PhD
Assistant Professor (Research), Center for Molecular Medicine and Genetics, Wayne State University School of Medicine
"MNRR1, a bi-organellar regulator at the fulcrum of cellular homeostasis"
12:30p NE1-205

Cancer Center Research Chalk Talk
Goutham Narla, MD, PhD
Associate Professor, Medicine, CWRU/UH
1p WRB 3-136
Wed, Jun 21
Hem/Onc Div Res Conf
8a Lerner B-151
Thurs, Jun 22
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology
1p SOM W203
Fri, Jun 23
TCI Grand Rounds
8a R3/002-003

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS

Cancer Stem Cell Retreat 
Jun 16, 2017
Cleveland Clinic
ASCO Review 
Jun 28, 2017
InterContinental Hotel

AACI Clinical Research Initiative Meeting
Jul 12-13, 2017
Loews Chicago O'Hare Hotel
Details

Mesenchymal Stem Cell Conference 2017
Aug 14-16, 2017
Marriott Key Center   

International Cancer Education Conference
Sep 13-15, 2017
Westin Cleveland Downtown

GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Pre-Application: Jun 14, 2017
Application: Aug 24, 2017

Pre-Application: Jun 21, 2017
Application: Sep 6, 2017

Pre-Application: Jun 21, 2017
Application: Sep 6, 2017

Pre-Application: Jun 21, 2017
Application: Sep 6, 2017


Pre-Application: Jun 28, 2017
Application: Sep 27, 2017

Pre-Application: Jun 28, 2017
Application: Sep 27, 2017

Pre-Application: Jun 28, 2017
Application: Sep 27, 2017

Pre-Application: Jun 30, 2017
Application: Sep 28, 2017

Pre-Application: Jun 30, 2017
Application: Sep 28, 2017


Deadline: Jul 6, 2017

Deadline: Jul 7, 2017

LOI: Jul 13, 2017
Application: Oct 5, 2017

Pre-Application: Jul 27, 2017
Application: Aug 10, 2017

LOI: Sep 12, 2017
Application: Sep 28, 2017

Pre-Application: Sep 13, 2017
Application: Sep 27, 2017


Deadline: Open

Deadline: Open

Case Comprehensive Cancer Center 
11100 Euclid Avenue, Wearn152
Cleveland, OH 44106-5065